We provide new evidence indicating CD4+GranzB+CTLs, in addition to CD8+GranzB+CTLs, may be involved in the pathophysiology of pSS, which may serve as a new biomarker to evaluate the disease activity and severity of pSS. The gene discussed is CD4; the disease is peeling skin syndrome.